Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Jankovic

Showing results (311-320 of 574) with videos related to

Pageof 58
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2003
Substantia nigra lesions in viral encephalitisCharulata Sankhla Savant, B S Singhal, Joseph Jankovic, et al.
Neuroscience Letters|May 8, 2007
Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's diseaseHao Deng, Weidong Le, Maosheng Huang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 13, 2010
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremorGiovanni Mostile, Joseph P Giuffrida, Octavian R Adam, et al.
Neurobiology of Disease|July 22, 2008
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancementTianhong Pan, Seiji Kondo, Wen Zhu, et al.
Neurochemistry International|June 16, 2010
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cellsYuncheng Wu, Xinqun Li, Wenjie Xie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 28, 2016
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's diseaseAlexander I Tröster, Joseph Jankovic, Michele Tagliati, et al.
Journal of the Neurological Sciences|July 19, 2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaCynthia L Comella, Joseph Jankovic, Daniel D Truong, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|June 17, 2011
Transcutaneous electrical stimulation (TENS) for psychogenic movement disordersJoseph Ferrara, William Stamey, Adriana M Strutt, et al.
Journal of Neurochemistry|July 24, 2010
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's diseaseWenjie Xie, Xuping Li, Chao Li, et al.
Neurology and Therapy|May 23, 2015
Effect of tetrabenazine on motor function in patients with huntington diseaseJoseph M Ferrara, Giovanni Mostile, Christine Hunter, et al.
Pageof 58

Showing results (311-320 of 574) with videos related to

Sort By:
Pageof 58
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2003
Substantia nigra lesions in viral encephalitisCharulata Sankhla Savant, B S Singhal, Joseph Jankovic, et al.
Neuroscience Letters|May 8, 2007
Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's diseaseHao Deng, Weidong Le, Maosheng Huang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 13, 2010
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremorGiovanni Mostile, Joseph P Giuffrida, Octavian R Adam, et al.
Neurobiology of Disease|July 22, 2008
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancementTianhong Pan, Seiji Kondo, Wen Zhu, et al.
Neurochemistry International|June 16, 2010
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cellsYuncheng Wu, Xinqun Li, Wenjie Xie, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 28, 2016
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's diseaseAlexander I Tröster, Joseph Jankovic, Michele Tagliati, et al.
Journal of the Neurological Sciences|July 19, 2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaCynthia L Comella, Joseph Jankovic, Daniel D Truong, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|June 17, 2011
Transcutaneous electrical stimulation (TENS) for psychogenic movement disordersJoseph Ferrara, William Stamey, Adriana M Strutt, et al.
Journal of Neurochemistry|July 24, 2010
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's diseaseWenjie Xie, Xuping Li, Chao Li, et al.
Neurology and Therapy|May 23, 2015
Effect of tetrabenazine on motor function in patients with huntington diseaseJoseph M Ferrara, Giovanni Mostile, Christine Hunter, et al.
Pageof 58